

**TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)**

8484-029-999

08/913139

INTERNATIONAL APPLICATION NO.  
PCT/DE96/00369

INTERNATIONAL FILING DATE  
March 1, 1996

PRIORITY DATE CLAIMED  
March 1, 1995

INVENTOR

**BODIES ACTIVE AGAINST A FUSION POLYPEPTIDE COMPRISING A HISTIDINE PORTION**

APPLICANT(S) FOR DO/EO/US

Hanswalter ZENTGRAF, Claudia TESSMER, Iris VELHAGEN, Susanne Schwinn, Manfred FREY

Applicant herewith submits to the United States Designated/ Elected Office (DO/EO/US) the following items under 35 U.S.C. 371:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☒ is transmitted herewith (required only if not transmitted by the international Bureau).
  - b. ☐ has been transmitted by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☒ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureaus.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
8. ☒ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 37(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.  
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☒ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:

One Small Entity Declaration  
International Search Report  
Preliminary Examination Report

INTERNATIONAL APPLICATION NO.  
PCT/DE96/00369

INTERNATIONAL FILING DATE  
March 1, 1996

17. ☒ The U.S. National Fee (35 U.S.C. 371(c)(1)) and other fees as follows:

CLAIMS

(1)FOR	(2)NUMBER FILED	(3)NUMBER EXTRA	(4)RATE	(5)CALCULATIONS
TOTAL CLAIMS	16 -20=	0	X \$ 22.00	\$ 0.00
INDEPENDENT CLAIMS	3 -3=	0	X \$ 80.00	0.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$ 260.00	260.00
BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)): <b>CHECK ONE BOX ONLY</b>				
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) ..... \$ 700				
<input type="checkbox"/> No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) ..... \$ 770				
<input checked="" type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$1040				1040.00
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2) to (4) ..... \$ 96				
<input type="checkbox"/> Filing with EPO or JPO search report ..... \$ 910				
Surcharge of \$130.00 for furnishing the National fee or oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 mos. from the earliest claimed priority date (37 CFR 1.492(e)).				130.00
TOTAL OF ABOVE CALCULATIONS				= 1,430.00
Reduction by 1/2 for filing by small entity, if applicable. Affidavit must be filed also. (Note 37 CFR 1.9, 1.27, 1.28).				- 715.00
SUBTOTAL				= 715.00
Processing fee of \$130.00 for furnishing the English Translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 mos. from the earliest claimed priority date (37 CFR 1.492(f)).				+ 0.00
TOTAL FEES ENCLOSED				\$ 715.00

- a. ☐ A check in the amount of \$ \_\_\_\_\_ to cover the above fees is enclosed.
- b. ☒ Please charge Deposit Account No. 16-1150 in the amount of \$ 715.00 to cover the above fees. A copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 16-1150. A copy of this sheet is enclosed.

18. ☒ Other instructions  
Please include the changes to the claims from the Preliminary Amendment before calculating the fee.

19. ☒ All correspondence for this application should be mailed to  
PENNIE & EDMONDS LLP  
1155 AVENUE OF THE AMERICAS  
NEW YORK, NEW YORK 10036-2711

20. ☒ All telephone inquiries should be made to (212) 790-2803

Jon R. Stark  
NAME

SIGNATURE

30,111  
REGISTRATION NUMBER

2 SEPT 97  
DATE

**ANTIBODIES ACTIVE AGAINST A FUSION POLYPEPTIDE  
COMPRISING A HISTIDINE PORTION**

---

**TABLE OF CONTENTS**

	<u>Page</u>
I. FIELD OF THE INVENTION . . . . .	1
II. BACKGROUND OF THE INVENTION . . . . .	1
III. SUMMARY OF THE INVENTION . . . . .	1
IV. DETAILED DESCRIPTION OF THE INVENTION . . . . .	2
V. EXAMPLES . . . . .	3
A. Example 1: Preparation Of Monoclonal Antibodies . . . . .	4
B. Example 2: Preparation Of Polyclonal Antibodies . . . . .	5
C. Example 3: Detection of histidine fusion polypeptides by antibodies according to the invention . . . . .	6
CLAIMS . . . . .	8
NEW CLAIMS FILED DURING CHAPTER II PROCEDURE ON APRIL 11, 1997 . . . . .	9
ABSTRACT . . . . .	10